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Abstracts
Background: Standardized Korean red ginseng extract has become the best-selling influenza-like illness (ILI)
remedy in Korea, yet much controversy regarding the efficacy of the Korean red ginseng (KRG) in reducing ILI
incidence remains. The aim of the study is to assess the efficacy of the KRG extract on the ILI incidence in healthy
adults.
Methods/Design: We will conduct a randomized, double-blind, placebo-controlled study at the onset of the
influenza seasons. A total of 100 subjects 30-70 years of age will be recruited from the general populations. The
subjects will be instructed to take 9 capsules per day of either the KRG extract or a placebo for a period of 3
months. The primary outcome measure is to assess the frequency of ILI onset in participated subjects. Secondary
variable measures will be included severity and duration of ILI symptoms. The ILI symptoms will be scored by
subjects using a 4-point scale.
Discussion: This study is a randomized placebo controlled trial to evaluate the efficacy of the KRG extract
compared to placebo and will be provided valuable new information about the clinical and physiological effects of
the KRG extract on reduction of ILI incidence including flu and upper respiratory tract infections. The study has
been pragmatically designed to ensure that the study findings can be implemented into clinical practice if KRG
extract can be shown to be an effective reduction strategy in ILI incidence.
Trial Registration: NCT01478009.
Background
Respiratory viruses are a major cause of influenza-like
illness(ILI) symptoms in children and adults, leading to
substantial morbidity and mortality each year [1-5]. The
complications of ILI symptoms may occur in young
children (< 1 year old) and elderly people (> 65 years
old), even though ILI symptoms is most often self-lim-
ited and restrained to the upper respiratory tract [6-8].
The ILI symptoms is characterized by sudden onset of
symptoms such as high fever (> 38°C) and cough in the
absence of other diagnosis [9,10]. Other symptoms
including myalgia, headache, chills and fatigue can only
be used as optional inclusion criteria. Although it is
known that rhinovirus infections cause 10% to 40% of
the upper respiratory tract infection [11], with corona-
virus, parainfluenza virus, adenovirus, echovirus, and
coxsackievirus accounting for the remainder of cases
[12,13], these viruses produce clinically indistinguishable
disease, making specific viral diagnosis difficult [14,15].
Many patients use complementary and alternative
medicine (CAM) therapies to treat and prevent the
acute respiratory illness in the worldwide. Moreover,
few physicians are familiar with their efficacy or safety.
Ginseng has been traditionally used in Asia for thou-
sands of years to treat a variety of ailments. The putative
active compounds derived from ginseng root processing
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are the ginsenosides (saponin glycosides), and the water-
soluble poly and oligosaccharides [16]. Various studies
have shown that both families of compounds can modu-
late various parameters of the immune response in vitro
and in vivo. In clinical trials, healthy subjects that con-
sumed a standardized ginseng extract had a lower inci-
dence of influenza and colds, higher antibody titers, and
higher natural killer cell activity [17], as well as
increased numbers of total lymphocytes and T helper
cells [18]. Ginseng polysaccharide preparations increased
cytokine production and mRNA expression by murine
macrophages and spleen cells in vitro [19-21].
Currently, the ginseng was well known effect for
improving the quality-of-life and immunomodulating
effects [21-24]. However, there has been no data on the
Korean red ginseng (KRG) accumulated for its preven-
tive activity against ILI onset, as it has shown in Ameri-
can ginseng. The purpose of this study is to evaluate the
efficacy of the KRG extract in reducing the frequency,
severity and duration of ILI symptoms in healthy adults.
Methods/Design
Study objectives
The objectives of this RCT are to study whether the
concentrated KRG extract can reduce the frequency,
severity, and duration of ILI symptoms in healthy
subjects.
Primary objective
To evaluate the efficacy of the KRG extract on the fre-
quency of ILI onset in healthy subjects after 12 weeks of
consumption.
Secondary objectives
To evaluate the following factors in healthy subjects
after 12 weeks of consumption on:
A) severity of ILI symptoms
B) duration of ILI symptoms
Ethics
The study protocol and the written informed consent
were approved by the Functional Foods Institutional
Review Board of Chonbuk National University Hospital
(CUH IRB 2010-02-016). Each subject will be notified
regarding the study protocol. Written informed consent
will be obtained from each subject.
Study/trial design
This study is a randomized, double-blind, placebo-con-
trolled, two-armed parallel clinical trial, comparing the
KRG extract to placebo. The design of the study will inte-
grate rigorous in accord with principles set out in the
Declaration of Helsinki and the Good Clinical Practice
guidelines. Our study plan is summarized in Figure 1.
Inclusion criteria for participation in the trial
Inclusion criteria
Subjects will be included if they meet the following cri-
teria:
A) Healthy volunteers aged 30 to 70 years
B) Ability to give informed consent
Exclusion criteria
The exclusion criteria for the study were:
A) Influenza vaccinated subjects
B) HIV infected and cancer patients
C) Cardiovascular disease, neurologic or psychiatric
disease, renal, pulmonary and hepatic abnormalities
D) Upper respiratory infection within two weeks
before study
E) History of disease that could interfere with the
test products or impede their absorption, such as
gastrointestinal disease (Crohn’s Disease) or gastro-
intestinal surgery (a caesum or enterocele surgery
are included)
F) Taking medications such as immunosuppressive
drugs, corticosteroids, warfarin, phenalzine, pento-
barbital, haloperidol, cyclosporine










































Figure 1 Flow diagram for study. Summary of the study flow.
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H) Laboratory test, medical or psychological condi-
tions deemed by the investigators to interfere with
successful participation in the study
I) History of drug or alcohol abuse in prior 2
months
Recruitment
100 subjects will be recruited through local advertising
and doctor referrals from hospital outpatients and gen-
eral practice clinics. Interested subjects can telephone or
email the trial coordinators at the trial conducting sites
for further information. Subject information and consent
forms will be sent to interested individuals to read over
prior to scheduling their first visit.
Randomization
After enrollment, subjects will be randomly assigned to
one of the two groups, either the KRG group or placebo
group. The allocation ratio will be 1:1 in blocks of 2.
Randomization will be performed at a site remote from
trial location. Random numbers will be generated by a
computerized random-number generator through the
block-randomization method of a software program
(Excel, Microsoft Office 2007) for sequence generation.
At the time of randomization subjects will draw an
envelope. Each envelope contains a number that is con-
cealed to the treatment allocation. Randomization
sequence and allocation will be concealed to all study
subjects, research staff, investigators and pharmacists
until completion of the study. The allocation list will be
protected by password access files and held by a non-
investigator independent. In the event of an emergency
medical situation the individual’s randomization code
and group allocation can be identify.
Outcome measures
Subjects will be asked open-ended questions about fre-
quency, severity, and duration of ILI symptoms during
telephone follow-ups on days 1, 28, 57, and 85 of treat-
ment and days 35 post-treatment. Subjects will be also
asked to report the study nurse immediately (within 24
hours), at the onset of ILI symptoms. Any unfavorable
or unintended sign or symptom will be documented.
Primary outcome
The primary outcome is the frequency of ILI symptom
onset. Subjects will be asked open-ended questions
about frequency of ILI onset during study period. The
frequency of ILI onset will be checked weekly via
telephone.
Secondary outcomes
Secondary outcomes will be variety ILI symptoms
(including fever, rhinorrhea, nasal congestion, sore
throat, cough, sputum, dyspnea, diarrhea, mawkishness,
vomiting, headache, and myalgia), severity of ILI symp-
toms, and duration of ILI symptoms. These outcomes
will be checked weekly via telephone. The schedule of
assessments is presented in Table 1.
ILI assessments
Subjects will be asked to record if they experienced any
of the following 8 symptoms: sore throat, runny nose,
nasal congestion, sneezing, hoarseness, myalgia, ear-
aches, fever, headache, and cough (Table 2). In this self-
assessment, subjects will be recorded the number of
days they experienced each symptom. Subjects will be
contacted by telephone each week to report the ILI
symptoms and to assure compliance to the study proto-
col. They will be also asked to record if the study medi-
cation helped in shortening duration of their symptoms,
and to list any additional medications taken for the
symptoms. Subjects will be recorded daily symptom
severity in a journal using a 4-point severity score index
(0 = no symptom, 1 = mild symptom, 2 = moderate
symptom and 3 = severe symptom).
Statistical analysis
Baseline data and Outcomes data
The effects of KRG extract or placebo treatment on the
frequency, severity, and duration of symptoms related to
ILI prior to the onset of influenza season will be ana-
lyzed. The Pearson chi-square test or Fisher’s exact test
(if the minimum expected count will be less than 2 or the
ratio of expected counts lower than 5 will be more than
20%) will be used to compare the proportions of subjects
reporting symptoms related to ILI and adverse events.
The data will be analyzed for all of the subjects who had
been randomly assigned to a group, excluding those who
provided only baseline information. An intention-to-treat
and per-protocol analysis will be performed.
For the subset of subjects who reported ILI-related
symptoms, the total score of severity and the duration
for which symptoms will be reported and the two
groups will be compared using Mann Whitney U test
between two groups. A value of p < 0.05 will be consid-
ered statistically significant.
Adverse events and monitoring safety
All unexpected adverse events related to KRG intake
will be reported to the investigator by subjects and write
on the individual case report form by the investigator.
Safety will be assessed by the reporting of clinical
laboratory tests, vital sign measurements, and adverse
events. Clinical laboratory tests, including AST/ALT,
BUN/creatinine, red blood cell (RBC) count, white
blood cell (WBC) count, hemoglobin, hematocrit, num-
ber of platelets, and number of differentiated cells will
be determined at weeks 0 (baseline) and 12 (end of the
trial). Vital signs of each subject will be checked with
monitoring of adverse events (nausea/vomiting, fatigue,
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allergic reaction, and any adverse events related to KRG
extract intake) after each visit.
Compliance
The KRG soft capsules remaining after each visit will be
quantified in order to enhance medication compliance.
Subjects whose compliance with the KRG extract cap-
sules is ≤ 70% of the total dose will be considered to
have dropped-out.
Sample size
This pilot study is the first clinical trials using KRG
extract for Korean population. So, there was limited
information about the prevention of influenza incidence
or symptom releases. Therefore, we had designed a pre-
liminary test using total 100 participants (50:50).
Discussion
In this study, we will examine whether the KRG extract
administration can significantly reduce the frequency,
severity, and duration of ILI symptoms. A 1000-mg dose
of KRG will be taken 3 times daily by subjects for 12
weeks. Initial ILI symptoms will be confirmed by the
collaborating physician at the screening visit of self-
reported ILI symptoms, and relief of symptoms will be
confirmed within 7 day of the subject’s self-reported
recovery. Subjects will be recorded daily symptom sever-
ity in a journal using a 4-point severity score.
The aim of this study is to evaluate the efficacy of the
KRG extract on the frequency, severity, and duration of
ILI symptoms. For this purpose, the ability of the KRG
extract to reduce the ILI incidence will be assessed in
100 healthy volunteers.
In this study, we expect that the KRG extract can
effectively reduce the ILI incidence. Some studies have
assessed the relative potency of ginseng extracts by eval-
uating their ability to prevent the upper respiratory tract
infections. The ginseng extracts has been studied in 3
recent RCTs to prevent the common cold, the flu, or
upper respiratory infections. Two studies did not show
differences between the ginseng extract and placebo in



















Informed consent form ◯
Demographic information taking1 ◯
Medical history taking ◯ ◯ ◯ ◯ ◯
Inclusion/exclusion criteria check ◯ ◯
Physician examination2 ◯ ◯
Vital sign measurement ◯ ◯ ◯ ◯ ◯
Concomitant drugs check ◯ ◯ ◯ ◯ ◯
Electrocardiogram(ECG) ◯ ◯
Questionnaires for symptoms related to ILI3 ◯ ◯ ◯ ◯ ◯ ◯
Laboratory test4 ◯ ◯
Study product distribution ◯ ◯ ◯
Compliance checking ◯ ◯ ◯
Adverse event monitoring ◯ ◯ ◯ ◯
◯ : Item need to be performed during the visit
1 Sex, date of birth, age, contact address and phone number
2 Include present illness, past history taking
3 Frequency of ILI symptom onset, severity of ILI symptoms, and duration of ILI symptoms
4 Blood test (WBC, RBC, hemoglobin, hematocrit, platelets count, AST, ALT, ALP, gamma-GTP, albumin, BUN, creatinine, glucose, total bilirubin, total protein), urine test
(specific gravity, pH, protein, ketone, glucose, bilirubin, urobilinogen, nitrite, microscopic (RBC, WBC))
Table 2 Questionnaire for Influenza-Like Illness
Symptoms Score Duration (days) nonattendance
(days)
Sore throat □0 □1 □2 □3
Runny nose □0 □1 □2 □3
Nasal congestion □0 □1 □2 □3
Sneezing □0 □1 □2 □3
Hoarseness □0 □1 □2 □3
Myalgia □0 □1 □2 □3
Earaches □0 □1 □2 □3
Fever □0 □1 □2 □3
Headache □0 □1 □2 □3
Cough □0 □1 □2 □3
Total score
0: None symptoms 1: Mild symptoms
2: Moderate symptoms 3: Severe symptoms
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terms of decreasing duration, severity, or frequency of
overall symptoms [25,26]. One study demonstrated that
the ginseng extracts decreased duration, severity, and
frequency of symptoms [27].
To the best of our knowledge, there has been no
report demonstrating the preventive efficacy of KRG
extract on ILI incidence. Therefore, if this study will be
successfully performed, the KRG extract may offer bene-
ficial effects in reducing ILI incidence. And these results
will be applied to children and elderly populations. To
draw confirmative conclusion about the preventive effi-
cacy and safety of the KRG extract on ILI incidence, a
full-scale RCT is being conducted now. If there are any
conclusions in the near future, we would like to publish
them later.
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